Conforma Therapeutics Appoints Former Lilly Executive, Christopher LeMasters, as Vice President, Corporate Development.Business Editors/Health/Medical Writers BIOWIRE2K SAN DIEGO--(BUSINESS WIRE)--April 19, 2004 Conforma Therapeutics Corporation today announced the appointment of Christopher C. LeMasters to the newly created position of Vice President, Corporate Development. Prior to joining Conforma, Mr. LeMasters worked for six years in Corporate Business Development at Eli Lilly and Company Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company and one of the world's largest corporations. Eli Lilly's global headquarters is located in Indianapolis, Indiana, in the United States. in Indianapolis. In that role, he was responsible for the successful negotiation of numerous research and development collaborations across diverse therapeutic areas. Additionally, he led or contributed to multiple strategy development projects, and was instrumental in the redesign of Lilly's licensing processes and organization. Prior to Lilly, he was a management consultant with Coopers & Lybrand Consulting in Chicago for four years, where he led strategy consulting projects for Fortune 500 clients. He began his business career as an operational auditor for Owens-Corning Fiberglas in Toledo. "Conforma will benefit greatly from Chris' broad strategic and business development experience," said Lawrence C. Fritz, Ph.D., president and chief executive officer of Conforma. "We expect that he will play a key role in advancing our strategic growth through in-licensing of new programs and products, and selective corporate partnering of our internally-developed drugs and technologies. I am pleased to welcome him to the Conforma management team." Mr. LeMasters has a B.A. in Finance from Indiana University Indiana University, main campus at Bloomington; state supported; coeducational; chartered 1820 as a seminary, opened 1824. It became a college in 1828 and a university in 1838. The medical center (run jointly with Purdue Univ. and an M.B.A. with Honors from the University of Chicago. About Conforma Therapeutics Conforma Therapeutics, a San Diego-based biopharmaceutical company, is focused on the design and development of novel drugs for the selective treatment of cancer. Conforma is developing drugs that target the cellular HSP (Hosting Service Provider) An organization that specializes in hosting Web sites. There are various levels of offerings from sharing a Web server with several other companies to having a dedicated Web server or to providing co-location services. See co-location. 90 family of molecular "chaperones" that control protein shape or conformation con·for·ma·tion n. One of the spatial arrangements of atoms in a molecule that can come about through free rotation of the atoms about a single chemical bond. , including that of key signaling molecules signaling molecules substances synthesized by cells for purposes of extracellular communication between cells. involved in the growth and survival of tumor cells. HSP90-directed drugs selectively induce the degradation of these cancer-promoting proteins, leading to tumor cell death. In addition to cancer, Conforma's technology also promises to have applications in other areas of medicine, including inflammation, virology virology, study of viruses and their role in disease. Many viruses, such as animal RNA viruses and viruses that infect bacteria, or bacteriophages, have become useful laboratory tools in genetic studies and in work on the cellular metabolic control of gene expression , and central nervous system disorders Nervous system disorders A satisfactory classification of diseases of the nervous system should include not only the type of reaction (congenital malformation, infection, trauma, neoplasm, vascular diseases, and degenerative, metabolic, toxic, or deficiency . Conforma's lead product, CNF CNF Configuration (File Name Extension) CNF Conference CNF Conjunctive Normal Form CNF Could Not Find CNF Chin National Front (Burma) CNF Canadian Nature Federation CNF Cornell NanoScale Facility 1010, is expected to enter the clinic in 2004 for the treatment of cancer, and will be followed by a pipeline of differentiated, molecularly targeted oncology products. Additional information regarding Conforma is available at www.conformacorp.com. |
|
|||||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion